OM:SOBIBiotechs
What Swedish Orphan Biovitrum (OM:SOBI)'s Expanded Real‑World Data at EHA2026 Means For Shareholders
In June 2026, Sobi announced that new clinical and real-world data for Aspaveli, Doptelet, Gamifant and Vonjo across multiple blood disorders were presented at the European Hematology Association Congress in Stockholm.
This broad data package, spanning long-term effectiveness, safety, treatment patterns and patient-reported outcomes, highlights how Sobi is building an evidence base around its core haematology portfolio beyond initial approvals.
We’ll now examine how this expanded real-world...